Ruijin Hospital

This early-stage trial tests whether adding sonrotoclax to standard Pola-R-CHP chemotherapy can improve outcomes for people with untreated large B-cell lymphoma that has high BCL2 expression or double-hit features. The study has two parts: first, finding a safe dose of sonrotocla…

This trial tests whether giving patients a special type of donor immune cell, called CD45RA-depleted DLI, can prevent serious viral infections after a stem cell transplant. The study includes 30 high-risk patients who have received a transplant for blood cancer. Researchers will …

This pilot study tests a new device that uses radiofrequency energy to calm overactive kidney nerves, which can drive high blood pressure. Twenty adults with untreated mild hypertension will either get the real procedure or a sham (fake) one. The main goal is to see if the real t…

This study tests a new nasal spray treatment for frontotemporal dementia (FTD), a brain disease that changes personality and language. The spray contains tiny particles from umbilical cord stem cells that may protect brain cells and reduce harmful protein buildup. About 33 adults…

This study looks at whether icosapent ethyl, a purified fish oil medication, can reduce inflammation and improve heart structure in people with coronary artery disease. Researchers will follow 420 patients for one year, comparing those who receive standard care plus icosapent eth…

This Phase 2 trial tests whether adding the migraine drug rimegepant to a standard CAR-T cell therapy and another immunotherapy (glofitamab) can improve outcomes for people with high-risk relapsed or refractory large B-cell lymphoma. About 100 adults will be randomly assigned to …

This study tests a personalized treatment approach for people with large B-cell lymphoma whose cancer did not respond to CAR-T cell therapy. Researchers will analyze the tumor's surrounding environment to classify it into one of four subtypes, then give patients a drug combinatio…

This study compares an AI-driven treatment strategy to standard therapy (Pola-R-CHP) for people with previously untreated large B-cell lymphoma. About 178 participants will be grouped by risk using an AI model, and those at intermediate or high risk will receive either a personal…

This early-phase trial tests a new CAR-T cell therapy called GI001 in 9 adults with relapsed or refractory B-cell lymphoma. Participants receive a single infusion of engineered immune cells designed to attack cancer. The main goals are to check safety and find the right dose, wit…

This study looks at a new way to give radiation to children with brain tumors that need whole-brain and whole-spine treatment. The technique, called vertebral body-sparing proton therapy, aims to protect the front of the spine bones to preserve bone marrow and growth. Researchers…

This study looks at whether giving hydrocortisone for one month after adrenal gland removal can slow kidney function decline in patients with primary aldosteronism and chronic kidney disease. About 90 adults will be randomly assigned to receive either hydrocortisone or standard c…

This phase 2 trial tests a combination of seven drugs (CL-Pola-R-CHP) in 28 adults aged 65 and older with double or triple-hit diffuse large B-cell lymphoma who are not eligible for transplant. The goal is to see how many patients achieve complete remission after six cycles of tr…

This early-phase study tests whether a combination of three drugs (sonrotoclax, zanubrutinib, and obinutuzumab) can shrink or eliminate mantle cell lymphoma in people with high-risk forms of the disease. About 28 newly diagnosed adults will receive the treatment and be monitored …

This study tests a vaccine called KSD-101 in 80 people with blood cancers linked to the Epstein-Barr virus (EBV). The vaccine uses a patient's own immune cells to target EBV and cancer. Researchers want to see if it can shrink tumors or keep the disease from coming back.

This study tests whether a new drug combination (C Pola R-CHP+X) works better than the standard treatment (CR-CHOP) for people with a fast-growing type of lymphoma called double-expressor diffuse large B-cell lymphoma. About 156 adults aged 18-75 who have not been treated before …

This study tests a new approach for people with a type of lymphoma (PTCL) that did not respond to initial chemotherapy. Doctors will use genetic testing of the tumor to choose a personalized combination of drugs, including an experimental drug called zeprumetostat. The goal is to…

This phase II trial tests a drug called cadonilimab combined with radiation therapy for women with advanced cervical cancer who cannot receive standard chemotherapy due to age or health issues. The study will enroll 45 participants and measure how many have a complete response (n…

This phase 2 trial tests a combination of zanubrutinib (a targeted drug) plus chemotherapy for people newly diagnosed with central nervous system lymphoma. Nineteen participants will receive the treatment, with an extra drug for those with a specific gene mutation. The goal is to…

This phase 2 trial is testing whether adding an experimental immunotherapy drug called SHR-1701 to standard chemotherapy can help people with stomach cancer that has spread to the lining of the abdomen. The study will enroll 60 adults and compare two different chemotherapy combin…

This early-stage trial will test a new drug called cizutamig in 15 people with moderate to severe ulcerative colitis who haven't improved with other treatments. The main goal is to check if the drug is safe and tolerable. It is not yet recruiting and will be conducted at a single…

This study tests a new drug called IBI363 combined with chemotherapy for people with advanced pancreatic cancer that has worsened after first treatment. About 48 patients will receive the combination to see if it is safe and helps control the cancer. The goal is to slow disease p…

This early-stage study tests a personalized mRNA vaccine (XP-006) for people with B-cell non-Hodgkin's lymphoma that has returned or not responded to treatment. The vaccine is custom-made to target each person's tumor. The main goal is to check safety and find the right dose, whi…

This study tests whether combining two powerful treatments—glofitamab and CAR-T therapy—can help people with a high-risk, hard-to-treat type of large B-cell lymphoma that has come back or not responded to prior treatment. About 24 adults will receive the combination and be monito…

This study tests whether spinal cord stimulation can help people with Parkinson's disease who experience sudden drops in blood pressure when standing up. Forty participants will receive either an implanted stimulator or a non-invasive version. The goal is to see if the treatment …

This study tests a new drug called BEBT-908 combined with chemotherapy in adults with a rare, high-risk form of acute lymphoblastic leukemia (ALL) who are in remission but still have tiny amounts of cancer cells detectable. The goal is to see if the combo can clear those leftover…

This study tests a new drug called QL1706 combined with chemotherapy for people with a type of esophageal cancer that is hard to remove with surgery. The goal is to shrink the tumor enough so that surgery can be done successfully. 24 adults with this cancer will receive the drug …

This phase 2 trial tests a combination of the drug golidocitinib plus chemotherapy (gemcitabine and oxaliplatin) in 31 adults with relapsed or refractory peripheral T-cell lymphoma, a rare and aggressive blood cancer. The goal is to see if the combo safely shrinks tumors and dela…

This study tests whether combining tazemetostat with either linperlisib or golidocitinib can safely shrink tumors in people with relapsed or refractory peripheral T-cell lymphoma. About 48 adults who have already tried at least one other treatment will receive the drugs by mouth.…

This study tests a new drug called gecacitinib for people with acute graft-versus-host disease (GVHD) after a stem cell transplant. It is for those who did not get better or could not tolerate the usual second-line treatment. The trial will include 15 adults and aims to see if th…

This early-phase trial will test the safety and tolerability of a new drug called cizutamig in 10 adults with systemic sclerosis, a rare autoimmune disease that causes skin and organ hardening. Participants must have moderate to severe skin involvement and have not responded well…

This early-phase trial tests a new drug called GB261 in 10 people with systemic sclerosis, a rare autoimmune disease that causes skin and organ hardening. The main goal is to check safety and how the body handles the drug. Researchers will also look for early signs that it might …

This study tests a new PET imaging tracer, [68Ga]Ga-NODAGA-SNA014, to detect a protein called Claudin18.2 in pancreatic and stomach cancers. The goal is to see if the scan can accurately identify patients whose tumors have this protein, which could help doctors choose the right t…

This study tests whether an ultrasound-based risk score can better predict and prevent pressure injuries (bedsores) in critically ill ICU patients. In phase 1, researchers will check how accurately the score identifies high-risk patients. In phase 2, some patients will receive nu…

This study compares two types of radiation therapy—proton and photon—given after breast cancer surgery to see which causes fewer side effects. Researchers will track 750 women for one year, monitoring heart, lung, skin, and lymph node problems. The goal is to find a gentler treat…

This study will test whether a partially hydrolyzed whey protein formula can help ease mild allergy symptoms in infants. About 160 babies with mild skin, stomach, or breathing issues will be randomly assigned to get either the special formula or a standard cow's milk formula. Res…

This study tests a new flu medicine called onradivir in teenagers aged 12 to 17 with uncomplicated influenza A. About 150 teens will receive either the drug or a placebo for 5 days. Researchers will track how fast flu symptoms like fever and body aches go away, and check for side…

This study tests two special formulas—amino acid formula (AAF) and extensively hydrolyzed formula (eHF)—in 360 infants aged 0-6 months with suspected cow's milk protein allergy. Babies will receive one formula for at least 2 weeks, and doctors will check if symptoms like diarrhea…

This study looks at how lying on your left side, right side, or back affects lung function in adults with acute respiratory distress syndrome (ARDS) after abdominal surgery. Researchers will use a special imaging technique called electrical impedance tomography to measure how wel…

This study will follow 1000 people diagnosed with peripheral T-cell lymphoma (PTCL) to see how different genetic subtypes affect disease progression and treatment response. Researchers will collect data from multiple hospitals and use genetic testing to classify patients. The goa…

This study will use a special PET/CT scan after proton radiation therapy for breast cancer to see how accurate the proton beam is. The goal is to link any beam errors with side effects like lung inflammation or rib fractures. By understanding these errors, doctors hope to improve…

This study tests whether using a bedside ultrasound to guide throat suctioning can reduce lung infections and injuries in ICU patients on breathing machines. About 321 adults expected to need a breathing tube for at least 72 hours will take part. The goal is to see if this imagin…

This observational study will analyze blood and sputum samples from 411 adults with acute respiratory distress syndrome (ARDS) who are on ventilators. Researchers will look for patterns in microbes, metabolites, and gene activity to see if they can predict how well patients respo…

Delirium is common in hospital intensive care units (ICUs) and can be hard to diagnose. This study will use non-contact cameras to analyze patients' facial micro-expressions and other biological signals. By combining this data with machine learning, researchers aim to build a mod…

This study will follow 1,000 people newly diagnosed with lymphoma to collect information on their treatments and outcomes. The goal is to learn which strategies work best in real-world settings, not to test a new drug. Participants must be at least 16 years old and have measurabl…